ABSTRACT
Both dental and cardiovascular disease are prevalent in the general population, have common risk factors and may be closely associated.Following cardiothoracic surgery, patients may be higher risk for developing infective endocarditis (IE) than the general population. Before cardiothoracic interventions, it is common practice for a dental assessment to be carried out and any necessary dental treatment provided. This aims to reduce the risk of IE arising from dental sources and avoid dental pain or infection during the peri- and post-operative period. There is little guidance on which treatments should be performed and when.Many patients with cardiac disease may have dental treatment provided safely in primary care. However, there is often a need to consider additional factors, including bleeding risk, condition stability or medication interactions. Dental teams must have an awareness of the implications of cardiac disease and provide reasonable adjustments to care provision where necessary, ensuring patient safety.This article proposes a protocol for dental management of patients awaiting cardiothoracic surgery and explores important considerations for dental care in this patient group.
Subject(s)
Dental Care , Humans , Risk Factors , Dental Care for Chronically Ill/methods , Cardiac Surgical Procedures , Endocarditis/prevention & control , Heart Diseases/surgery , Heart Diseases/complicationsABSTRACT
OBJECTIVE: Despite advancements in surgical techniques, operations for infective endocarditis (IE) remain associated with relatively high mortality. The aim of this study was to develop a nomogram model to predict the early postoperative mortality in patients undergoing cardiac surgery for infective endocarditis based on the preoperative clinical features. METHODS: We retrospectively analyzed the clinical data of 357 patients with IE who underwent surgeries at our center between January 2007 and June 2023. Independent risk factors for early postoperative mortality were identified using univariate and multivariate logistic regression models. Based on these factors, a predictive model was developed and presented in a nomogram. The performance of the nomogram was evaluated through the receiver operating characteristic (ROC) curve, calibration plot, and decision curve analysis (DCA). Internal validation was performed utilizing the bootstrapping method. RESULTS: The nomogram included nine predictors: age, stroke, pulmonary embolism, albumin level, cardiac function class IV, antibotic use <4weeks, vegetation size ≥1.5 cm, perivalvular abscess and preoperative dialysis. The area under the ROC curve (AUC) of the model was 0.88 (95%CI:0.80-0.96). The calibration plot indicated strong prediction consistency of the nomogram with satisfactory Hosmer-Lemeshow test results (χ2 = 13.490, p = 0.142). Decision curve analysis indicated that the nomogram model provided greater clinical net benefits compared to "operate-all" or "operate-none" strategies. CONCLUSIONS: The innovative nomogram model offers cardiovascular surgeons a tool to predict the risk of early postoperative mortality in patients undergoing IE operations. This model can serve as a valuable reference for preoperative decision-making and can enhance the clinical outcomes of IE patients.
Subject(s)
Cardiac Surgical Procedures , Decision Support Techniques , Endocarditis , Nomograms , Predictive Value of Tests , Humans , Retrospective Studies , Male , Female , Middle Aged , Cardiac Surgical Procedures/adverse effects , Cardiac Surgical Procedures/mortality , Risk Factors , Risk Assessment , Endocarditis/mortality , Endocarditis/surgery , Endocarditis/diagnosis , Time Factors , Aged , Treatment Outcome , Adult , Reproducibility of Results , Clinical Decision-MakingABSTRACT
INFECTIOUS ENDOCARDITIS: STRATEGY FOR DIAGNOSIS. The diagnosis of infective endocarditis is often difficult because the clinical presentations are very heterogeneous. Epidemiology has evolved with more acute forms, different microorganisms, and an increase in prevalence in patients with cardiac prosthetic or electronic devices. Diagnosis is based on a clinical suspicion, associated with microbiological data and imaging evidence of lesions of the endocardium. Echocardiography plays a key role, but advanced imaging techniques provide additional information. The 2023 European Society of cardiology (ESC) recommendations like those of 2015 confirmed the essential role of multimodal imaging, integrating lesions highlighted by any imaging technique as major criteria. The diagnostic criteria have thus been modified to consider new epidemiological and imaging data. Different diagnostic strategy algorithms are proposed depending on whether the patient has prosthetic material or not. The endocarditis team is the keystone in this diagnostic approach to improve patient management.
ENDOCARDITES INFECTIEUSES: DÉMARCHE DIAGNOSTIQUE. Le diagnostic d'endocardite infectieuse est souvent difficile, car les présentations cliniques sont hétérogènes. L'épidémiologie a évolué avec des formes plus aiguës, des micro-organismes différents et avec l'augmentation de la prévalence chez les patients porteurs de matériel intracardiaque. Le diagnostic repose sur une suspicion clinique supportée par des données microbiologiques et la mise en évidence de lésions de l'endocarde à l'imagerie. L'échocardiographie joue un rôle clé, mais les techniques avancées d'imagerie permettent d'améliorer les performances diagnostiques. Les recommandations de l'European Society of Cardiology (ESC) 2023, comme celles de 2015, ont confirmé le rôle essentiel de l'imagerie multimodale, intégrant comme critères majeurs les lésions mises en évidence par toute technique d'imagerie. Les critères diagnostiques ont été ainsi modifiés pour prendre en compte les nouvelles données épidémiologiques et d'imagerie. Différents algorithmes de stratégie diagnostique sont proposés selon que le patient est porteur de matériel prothétique ou non. L'équipe multidisciplinaire d'endocardite est la clé de voûte dans cette démarche diagnostique pour améliorer la gestion des patients.
Subject(s)
Endocarditis , Humans , Endocarditis/diagnosis , Endocarditis/therapy , Algorithms , Echocardiography/methods , Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/epidemiologyABSTRACT
TREATMENT OF INFECTIVE ENDOCARDITIS. Patients with infective endocarditis (IE) are taken care for by multidisciplinary teams. The treatment consists of antibiotic therapy initiated early, adapted to the responsible germ and prolonged, associated with surgical treatment when there is an indication for surgery. A parenteral antibiotic therapy is initiated in hospital for a period of at least two weeks. Depending on evolution of the patients, outpatient antibiotic treatment may be considered, and oral antibiotics may be proposed in stable patients when IE is caused by the most frequent germs. The surgical treatment of IE consists of total excision of the infected tissues and aims to restore the integrity of valvular functions. Conservative surgical treatment is performed, when possible, otherwise valve replacement is the alternative. The recognition of surgical indications (heart failure, uncontrolled infection, and prevention of embolic risk) is essential to improve the prognosis.
Subject(s)
Anti-Bacterial Agents , Endocarditis , Humans , Endocarditis/therapy , Endocarditis/diagnosis , Endocarditis/prevention & control , Anti-Bacterial Agents/therapeutic use , Endocarditis, Bacterial/therapy , Endocarditis, Bacterial/diagnosisABSTRACT
EUROPEAN REGISTRY OF INFECTIOUS ENDOCARDITIS. The EURO-ENDO registry was initiated in 2018. Its objectives were to assess the epidemiological, clinical, bacteriological, and prognostic features of infective endocarditis. Initially only European, it rapidly become a world registry including more than 3000 patients worldwide. EURO-ENDO confirms the drastic change in the profile of patients suffering from infective endocarditis, the important improvements in their management, but their persisting high mortality. EURO-ENDO also underlines the value of an early diagnosis of this disease as well as its management in highly specialized centers, with an experienced medical and surgical team.
REGISTRE EUROPÉEN DES ENDOCARDITES INFECTIEUSES. Le registre EURO-ENDO a été créé en 2018 pour préciser les caractéristiques épidémiologiques, cliniques, bactériologiques, diagnostiques et pronostiques de l'endocardite infectieuse. Initialement européen, il est en fait devenu un registre mondial incluant plus de 3 000 patients à travers le monde. Il confirme le changement radical du profil des patients atteints d'endocardite infectieuse, les grands progrès diagnostiques et thérapeutiques mais également la persistance d'une mortalité élevée chez des patients de plus en plus âgés et polypathologiques. Il souligne l'intérêt d'un diagnostic précoce permettant une prise en charge immédiate par une équipe médico-chirurgicale habituée à traiter cette pathologie complexe.
Subject(s)
Endocarditis , Registries , Humans , Europe/epidemiology , Endocarditis/epidemiology , Endocarditis/diagnosis , Endocarditis/therapy , Endocarditis, Bacterial/epidemiology , Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/therapyABSTRACT
INFECTIOUS ENDOCARDITIS: FROM EPIDEMIOLOGY TO PREVENTION. The incidence of infective endocarditis is estimated between 30 and 80 cases per million inhabitants and per year in the general population in industrialized countries. It is heterogeneous and increases sharply in the presence of certain underlying heart diseases; it exceeds 1% per year in patients with a history of endocarditis. Incidence increases after the age of 60 and Staphylococcus is now the most frequent responsible microorganism. Antibiotic prophylaxis is indicated only in the patients who are at high risk of infective endocarditis and who undergo invasive dental care. The recommendations published in 2023 by the European Society of Cardiology highlig.
ENDOCARDITES INFECTIEUSES: DE L'ÉPIDÉMIOLOGIE À LA PRÉVENTION. L'incidence de l'endocardite infectieuse est estimée entre 30 et 80 cas par million d'habitants et par an en population générale dans les pays industrialisés. Cette incidence est hétérogène et augmente très nettement dans certaines cardiopathies sous-jacentes : elle dépasse 1 % par an chez les patients ayant un antécédent d'endocardite. L'incidence est majorée après 60 ans, et le staphylocoque est désormais la bactérie la plus souvent en cause. L'antibioprophylaxie n'est indiquée que chez les patients ayant un risque élevé d'endocardite infectieuse et soumis à des soins dentaires invasifs. Les recommandations publiées en 2023 par l'European Society of Cardiology soulignent l'importance des mesures non spécifiques d'hygiène bucco-dentaire et cutanée dans la prévention.
Subject(s)
Endocarditis, Bacterial , Humans , Endocarditis, Bacterial/prevention & control , Endocarditis, Bacterial/epidemiology , Incidence , Antibiotic Prophylaxis , Endocarditis/prevention & control , Endocarditis/epidemiologyABSTRACT
COMPLICATIONS OF INFECTIVE ENDOCARDITIS. The high in-hospital mortality of patients with infective endocarditis (about 20%) is mainly due to its complications. These complications are essentially of cardiac, neurological, and infectious origin. Rapid diagnosis and early antibiotic treatment are of paramount importance and allow drastic reduction of the frequency and severity of such complications. Discussion with all physicians caring for the patients with infective endocarditis in an "endocarditis team" setting is a mandatory step in management optimization and outcome improvement. This "endocarditis team" approach allows faster identification of patients at high risk of acute heart failure and/or cerebral embolism, and selection of those who might benefit from urgent valvular surgery. Factors associated with high embolic risk are the size and mobility of vegetation, mitral valve endocarditis, and infection with Staphylococcus aureus. When neurological complications occur, there is a risk that these may be worsened by the valvular surgery if there is a hemorrhagic component. This risk needs to be careful weighed in a team approach before sending patients to surgery. Persistent sepsis after effective antibiotic treatments prompts to local extension of the disease or to embolic extra cardiac secondary infectious localization.
COMPLICATIONS DE L'ENDOCARDITE INFECTIEUSE. Les complications de l'endocardite infectieuse (EI) sont à l'origine d'une mortalité hospitalière élevée d'environ 20 %. Elles sont essentiellement cardiaques, neurologiques et septiques. Un diagnostic rapide et une antibiothérapie précoce sont essentiels, car ils permettent de réduire la fréquence et la sévérité de ces complications. Une discussion collégiale au sein de l'équipe pluridisciplinaire (endocarditis team) est indispensable pour optimiser la prise en charge et améliorer le pronostic. Elle permet notamment d'identifier rapidement les patients à haut risque d'insuffisance cardiaque aiguë et/ou d'embolie cérébrale et de sélectionner les patients nécessitant une chirurgie valvulaire urgente. Les facteurs prédictifs d'un haut risque embolique sont la taille et la mobilité de la végétation, sa localisation sur la valve mitrale et l'EI à Staphylococcus aureus. La survenue d'une complication neurologique nécessite une évaluation rigoureuse compte tenu des risques d'aggravation de la lésion par la chirurgie valvulaire en présence d'une composante hémorragique. Un sepsis persistant sous traitement antibiotique doit faire rechercher une extension locale de l'endocardite ou des foyers emboliques extracardiaques.
Subject(s)
Endocarditis , Humans , Endocarditis/etiology , Endocarditis/diagnosis , Endocarditis/complications , Endocarditis, Bacterial/etiology , Endocarditis, Bacterial/diagnosisABSTRACT
BACKGROUND: The current study presents a novel and precise surgical technique for complete reconstruction of the aortic valve using glutaraldehyde-treated autologous pericardium in a patient with aortic valve disease and endocarditis. The technique aims to provide a more effective and reproducible method for aortic valve repair, with the goal of improving outcomes and quality of life for patients with aortic valve disease. CASE PRESENTATION: A 35-year-old Iranian male with aortic valve disease and endocarditis underwent aortic valve reconstruction surgery. Preoperative echocardiography showed a degenerative aortic valve with severe regurgitation, reduced left ventricular ejection fraction, and specific aortic root dimensions. The surgical technique involved precise measurements and calculations to design the size and shape of the new aortic valve cusps using autologous pericardium, with the goal of optimizing coaptation and function. The surgeon calculated the intercommissural distance based on the aortic annulus diameter to determine cusp size and shape. He tailored the pericardial cusps to have a height equal to 80% of the coaptation margin length. Detailed suturing techniques were used to ensure proper alignment and coaptation of the new cusps. Intraoperative evaluation of the valve function using suction and transesophageal echocardiography showed good coaptation and minimal residual regurgitation. At the 3-year follow-up, the patient had a well-functioning aortic valve with only trivial leak and was in satisfactory clinical condition. CONCLUSIONS: Glutaraldehyde-treated autologous pericardium is a validated leaflet alternative, and the causes of its failure are late annular dilatation and other technique breakdowns. Current evidence reveals that aortic valve reconstruction with glutaraldehyde-treated autologous pericardium is associated with many advantages with the potential to improve patient outcomes and quality of life. Further clinical studies are warranted to evaluate the long-term durability and efficacy of this approach.
Subject(s)
Aortic Valve , Glutaral , Pericardium , Humans , Male , Pericardium/transplantation , Adult , Glutaral/therapeutic use , Aortic Valve/surgery , Aortic Valve/diagnostic imaging , Transplantation, Autologous , Aortic Valve Insufficiency/surgery , Aortic Valve Insufficiency/diagnostic imaging , Plastic Surgery Procedures/methods , Aortic Valve Disease/surgery , Treatment Outcome , Echocardiography, Transesophageal , Echocardiography , Endocarditis/surgeryABSTRACT
OBJECTIVES: To date, there are no standardized treatment algorithms or recommendations for patients with infective endocarditis (IE) and concomitant spondylodiscitis (SD). Therefore, our aim was to analyse whether the sequence of surgical treatment of IE and SD has an impact on postoperative outcome and to identify risk factors for survival and postoperative recurrence. METHODS: Patients with IE underwent surgery in 4 German university hospitals between 1994 and 2022. Univariable and multivariable analyses were performed to identify possible predictors of 30-day/1-year mortality and recurrence of IE and/or SD. RESULTS: From the total IE cohort (n = 3991), 150 patients (4.4%) had concomitant SD. Primary surgery for IE was performed in 76.6%, and primary surgery for SD in 23.3%. The median age was 70.0 (64.0-75.6) years and patients were mostly male (79.5%). The most common pathogens detected were enterococci and Staphylococcus aureus followed by streptococci, and coagulase-negative Staphylococci. If SD was operated on first, 30-day mortality was significantly higher than if IE was operated on 1st (25.7% vs 11.4%; P = 0.037) and we observed a tendency for a higher 1-year mortality. If IE was treated 1st, we observed a higher recurrence rate within 1 year (12.2% vs 0%; P = 0.023). Multivariable analysis showed that primary surgery for SD was an independent predictor of 30-day mortality. CONCLUSIONS: Primary surgical treatment for SD was an independent risk factor for 30-day mortality. When IE was treated surgically 1st, the recurrence rate of IE and/or SD was higher.
Subject(s)
Discitis , Recurrence , Humans , Male , Female , Aged , Discitis/surgery , Discitis/microbiology , Discitis/mortality , Middle Aged , Risk Factors , Retrospective Studies , Endocarditis, Bacterial/surgery , Endocarditis, Bacterial/mortality , Endocarditis, Bacterial/microbiology , Endocarditis/surgery , Endocarditis/mortality , Germany/epidemiology , Treatment OutcomeABSTRACT
BACKGROUND: New prosthetic valves and surgical approaches that shorten operation time and improve the outcome of patients with aortic valve (AV) infective endocarditis (IE) and AV insufficiency (AVI) are crucial. The aim of this study was to evaluate the outcome of patients with AV IE or AVI treated with the EDWARDS INTUITY Rapid-Deployment AV prosthesis for this off-label indication. METHODS: This single-centre retrospective study analyzed data from patients who underwent AV replacement with the EDWARDS INTUITY Rapid-Deployment AV prosthesis for AV IE or regurgitation. (n = 8 for IE and n = 6 for AVI). RESULTS: Heart-lung machine times were significantly shorter in the AVI group (111.3 ± 20.7 min) compared to the IE group (171.9 ± 52.4 min) (p = 0.02). Aortic cross-clamp followed a similar trend (73.7 ± 9.9 min for AVI vs. 113.4 ± 35.6 min for IE) (p = 0.02). The length of ICU stay was also shorter in the AVI group (3.8 ± 2.6 days) compared to the IE group (16.9 ± 8.9 days) (p = 0.005). Postoperative echocardiography revealed no paravalvular leakage or significant valvular dysfunction in any patient. One patient died postoperatively from aspiration pneumonia. CONCLUSION: The INTUITY valve demonstrates as a safe option for complex AV IE and AVI surgery. Further prospective studies with larger patient cohorts are necessary to confirm these findings and explore the long-term benefits of this approach.
Subject(s)
Aortic Valve Insufficiency , Aortic Valve , Endocarditis , Heart Valve Prosthesis Implantation , Heart Valve Prosthesis , Humans , Male , Retrospective Studies , Female , Middle Aged , Aortic Valve Insufficiency/surgery , Heart Valve Prosthesis Implantation/methods , Endocarditis/surgery , Endocarditis/complications , Aortic Valve/surgery , Aged , Treatment Outcome , AdultABSTRACT
INTRODUCTION: Infective endocarditis is a rare but potentially severe disease, associated with significant morbidity and mortality. Our study aims to describe the epidemiology and management aspects of endocarditis in northern Morocco and compare it with international management guidelines. MATERIALS AND METHODS: This is a retrospective study involving all patients hospitalized in the cardiology department of the University Hospital of Tangier for infective endocarditis over a period of 4 years and 7 months, from May 2019 to February 2024. RESULTS: Eighty patients were hospitalized for IE during the study period. The average age of the patients was 46 years, with an even sex ratio. IE concerned native valves in 77% of cases, mechanical prostheses in 19% of cases, and on bio prostheses in 4%. The average diagnostic delay was 25 days. Blood cultures were negative in 59% of cases. The predominant infective microorganism was the bacteria Staphylococcus (65.6%). Imaging results showed vegetations in 76.3% of cases, predominantly on the mitral valve (39.3%), followed by the aortic valve (21.3%). The main complications included heart failure (51.2%), peripheral arterial embolisms (22.5%) and splenic infarction (17.5%). Management wise, the most commonly used antibiotic therapy was a combination of ceftriaxone and gentamicin. Clinical and biological improvement was observed in 70% of cases, with a mortality rate of 12.5%. Twelve patients underwent surgery (15%). Urgent surgery was indicated in 66,7% of the operated patients. CONCLUSION: Our study highlights the challenges in managing infective endocarditis in northern Morocco. The prognosis of infective endocarditis can be improved through multidisciplinary management within the implementation of an Endocarditis Team.
Subject(s)
Anti-Bacterial Agents , Endocarditis , Humans , Morocco/epidemiology , Male , Female , Middle Aged , Retrospective Studies , Adult , Prognosis , Endocarditis/epidemiology , Endocarditis/microbiology , Endocarditis/diagnosis , Endocarditis/therapy , Endocarditis/mortality , Anti-Bacterial Agents/therapeutic use , Aged , Endocarditis, Bacterial/epidemiology , Endocarditis, Bacterial/microbiology , Endocarditis, Bacterial/mortality , Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/drug therapy , Young Adult , AdolescentABSTRACT
Background and Objectives: Determinants of long-term outcomes after surgery for native mitral valve endocarditis have not been thoroughly investigated. The aim of this study was to assess anatomical, disease, and surgical risk factors for long-term mortality and need of reintervention, in patients undergoing mitral valve surgery for active endocarditis. Materials and Methods: Patients who underwent surgery for active native mitral valve endocarditis at three academic centres, between 2000 and 2022, were analysed. The primary outcome was long-term survival. The secondary outcome was the freedom from mitral reoperation. Survival curves were constructed with Kaplan-Meier methodology. Multivariable Cox regression was used to identify demographic, anatomical, disease, and surgical factors associated with late mortality and reoperation. Results: 335 consecutive patients with active mitral endocarditis were analysed. Two hundred and one patients (70.5%) had infection confined to the valve cusp whereas 89 (25.6%) had invasive disease extended to the annulus and surrounding tissues. Preoperative neurological events occurred at the diagnosis in 52 cases. Streptococci were the most common causative organisms followed by Staphylococcus aureus, Coagulase-negative Staphylococcus, and Enterococcus. Valve repair was performed in 108 patients (32.2%). Survival at 5 and 10 years was 70.1% and 59.2%, respectively. Staphylococcus emerged as an independent predictor of late mortality, along with age, chronic obstructive pulmonary disease, and previous cardiac surgery. Survival was considerably reduced in patients with S. aureus compared with those without (log rank p < 0.001). The type of surgery (repair vs. replacement) did not emerge as a risk factor for late mortality and reoperation. Seventeen patients underwent mitral reoperation during the follow-up. The 5- and 10-year freedom from reoperation was 94.7% and 91.8%, respectively. Conclusions: Active mitral valve endocarditis remains a life-threatening disease with impaired survival. While lesion characteristics influenced surgical decision-making and intraoperative management, their impact on long-term survival and freedom from reintervention appears to be moderated by other factors such as infecting pathogens and patient comorbidities.
Subject(s)
Mitral Valve , Humans , Female , Male , Middle Aged , Mitral Valve/surgery , Aged , Reoperation/statistics & numerical data , Risk Factors , Treatment Outcome , Retrospective Studies , Endocarditis/surgery , Endocarditis/mortality , Adult , Proportional Hazards Models , Kaplan-Meier EstimateABSTRACT
INTRODUCTION: Congenital heart diseases (CHD) with abnormal turbulent blood flow are associated with the highest risk of infective endocarditis (IE). Despite advancement in diagnostics and treatment, the mortality rate of IE remains high due the life-threatening complications. Our study aims to assess the incidence and mortality rates of IE and predictive factors for mortality among adults CHD (ACHD). METHODS: A systematic literature search was conducted on PubMed, SCOPUS, and Ovid SP to retrieve relevant studies. The pooled estimates and predictors of mortality were calculated using the random-effects generic inverse variance method using R programming. RESULTS: 12 studies involving 3738 ACHD patients were included in this meta-analysis. The overall incidence of IE in ACHD was 1.26 per 1000 patient-years (95% CI 0.55-1.96). 60% (95% CI 46-72%) of patients had surgical management for IE. The mortality rate of IE was 9% (95% CI 7-12%). The predictors of mortality were conservative management (OR: 5.07, 95% CI: 4.63-5.57), renal dysfunction (OR: 4.15, 95% CI: 2.92-5.88), cerebral complications (OR: 3.59, 95% CI: 1.78-7.23), abscesses/valve complications (OR: 2.67, 95% CI: 1.71-4.16), Staphylococcus aureus infection (OR: 2.32, 95% CI: 1.33-4.06), emboli (OR: 2.03, 95% CI: 1.47-2.79), body mass index (OR: 1.10, 95% CI: 1.01-1.21), age (OR: 1.02, 95% CI: 1.00-1.04), and previous IE (OR: 1.02, 95% CI: 1.00-1.04). CONCLUSION: The mortality rate of IE in ACHD is low. However, conservative management is associated with the highest risk of mortality.
Subject(s)
Endocarditis , Heart Defects, Congenital , Humans , Heart Defects, Congenital/mortality , Heart Defects, Congenital/complications , Incidence , Endocarditis/mortality , Endocarditis/epidemiology , Endocarditis/diagnosis , Adult , Risk Factors , Predictive Value of Tests , Mortality/trendsABSTRACT
BACKGROUND: Infective endocarditis (IE) is a rare cardiovascular complication in patients with coronavirus disease 2019 (COVID-19). IE after COVID-19 can also be complicated by acute respiratory distress syndrome (ARDS); however, the guidelines for the treatment of such cases are not clear. Here, we report a case of perioperative management of post-COVID-19 IE with ARDS using veno-venous extracorporeal membrane oxygenation (V-V ECMO). CASE PRESENTATION: The patient was a 40-year-old woman who was admitted on day 18 of COVID-19 onset and was administered oxygen therapy, remdesivir, and dexamethasone. The patient's condition improved; however, on day 24 of hospitalization, the patient developed hypoxemia and was admitted to the intensive care unit (ICU) due to respiratory failure. Blood culture revealed Corynebacterium striatum, and transesophageal echocardiography revealed vegetation on the aortic and mitral valves. Valve destruction was mild, and the cause of respiratory failure was thought to be ARDS. Despite continued antimicrobial therapy, ARDS did not improve the patient's condition, and valve destruction progressed; therefore, surgical treatment was scheduled on day 13 of ICU admission. After preoperative consultation with the team, a decision was made to initiate V-V ECMO after the patient was weaned from CPB, with concerns about further worsening of her respiratory status after surgery. The patient returned to the ICU with transition to V-V ECMO, and her circulation remained stable. The patient was weaned off V-V ECMO on postoperative day 33 and discharged from the ICU on postoperative day 47. CONCLUSIONS: ARDS may occur in patients with IE after COVID-19. Owing to concerns about further exacerbation of pulmonary damage, the timing of surgery should be comprehensively considered. Preoperatively, clinicians should discuss perioperative ECMO introduction and configuration.
Subject(s)
COVID-19 , Extracorporeal Membrane Oxygenation , Perioperative Care , Respiratory Distress Syndrome , Humans , Female , Extracorporeal Membrane Oxygenation/methods , Adult , COVID-19/complications , Respiratory Distress Syndrome/etiology , Respiratory Distress Syndrome/therapy , Perioperative Care/methods , SARS-CoV-2 , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/therapy , Coronavirus Infections/complications , Coronavirus Infections/therapy , Endocarditis/complications , Endocarditis/surgery , Echocardiography, Transesophageal , BetacoronavirusSubject(s)
Endocarditis , Humans , Male , Female , Middle Aged , Endocarditis/surgery , Endocarditis, Bacterial/surgery , Adult , AgedABSTRACT
BACKGROUND Histoplasma capsulatum is prevalent in the mid-eastern United States and is an environmental fungus that causes human infection by the inhalation of its spores. It is commonly associated with areas containing large amounts of bird excrement and can survive for years in the soil. Only 1% of infected individuals develop disseminated histoplasmosis or Histoplasma endocarditis. CASE REPORT A 61-year-old man with atrial fibrillation had 8 months of fatigue, low-grade fevers, night sweats, and unexplained weight loss presented to the Emergency Department. He worked and lived in Central Florida and although he raised cattle, he denied exposure to birds or bats with regularity. A transesophageal echocardiogram confirmed a sessile echo density on the atrial surface of the mitral valve. His microbial Karius cell-free DNA test from his blood sample was positive for Histoplasma capsulatum, and he was immediately given intravenous liposomal amphotericin for 2 weeks. A tissue valve was used to successfully replace his mitral valve along with a coronary artery bypass and a maze procedure for his persistent atrial fibrillation and atrial flutter. The diagnosis of mitral valve endocarditis from disseminated histoplasmosis was confirmed by pathological analysis, and he was sent home on long-term itraconazole maintenance treatment. CONCLUSIONS Surgical intervention in combination with anti-fungal medication can be a lifesaving intervention for disseminated histoplasmosis. A thorough history is particularly important when evaluating a patient with an unknown infectious source, especially assessing for risk factors, including exposure to environmental factors, workplace, and animals.
